Related Experiment Videos
Use of aspirin in cardiovascular prophylaxis
Insights
Low-dose aspirin is proven for secondary prevention after myocardial infarction (MI) or stroke. High-risk individuals without prior events also benefit from aspirin, aiding clinical risk assessment.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- Established efficacy of low-dose aspirin for secondary prevention of vascular events (myocardial infarction, stroke, transient ischemic attack) based on randomized controlled trials.
- Debate surrounding aspirin's role in primary prevention stems from a misunderstanding of risk stratification.
- Prior clinical events are only one factor in assessing future vascular event risk.
Purpose of the Study:
- To clarify the established and debated roles of aspirin in vascular event prevention.
- To highlight the benefit of aspirin in high-risk individuals without prior clinical events.
- To discuss the clinical judgment involved in balancing aspirin's benefits against side-effect risks.
Main Methods:
- Review of major overviews of randomized controlled trials.
- Analysis of risk factors and clinical event history for patient stratification.
- Consideration of assumed benefits based on early intervention principles.
Main Results:
- Aspirin's prophylactic value is definitively established for secondary prevention.
- Trials confirm benefit for high-risk patients without prior vascular events.
- Early aspirin administration in myocardial infarction is presumed to maximize benefit.
Conclusions:
- Aspirin is crucial for secondary prevention of vascular events.
- High-risk individuals, even without prior events, benefit from aspirin.
- Clinical judgment is essential for personalized aspirin therapy, considering risk and side effects.
- Emerging research suggests potential new uses for aspirin in conditions like dementia and cancer.
Abstract:
The value of prophylatic low-dose aspirin in patients who have experienced a myocardial infarction (MI), stroke or transient ischaemic attack (TIA) has been established beyond all reasonable doubt in a number of major overviews of randomised controlled trials. The value of aspirin in so-called 'primary prevention' is debated, but discussions are based on a misunderstanding. The terms 'primary' and 'secondary' relate to past vascular events and the occurrence of a prior event is only one factor in the estimation of the risk of a future event. Trials have confirmed that patients at high risk, who have not already had a clinical event, do benefit from aspirin. The estimation of risk, and the balancing of this against the chance of undesirable side-effects from aspirin, constitutes a clinical judgement. Although there is only limited evidence from trials, it is reasonable to assume that the earlier aspirin is given in infarction, the greater the benefit is likely to be. This assumption underlies advice from a number of bodies that aspirin should be given by a doctor, nurse or paramedic on first contact with a patient experiencing sudden severe chest pain. Again, although there is no direct evidence from trials, it would seem reasonable to advise patients who have been judged to be at increased risk of infarction to carry aspirin tablets and to chew and swallow one or two immediately if they experience sudden severe chest pain. Aspirin has a fascinating history. The new uses now being suggested, namely in the management of dementia, cancer and other conditions, make it likely that it will have an even more fascinating future.